Monday

Clinical Trials

The Clinical Trials session featured studies on biomarker-guided prostate cancer care, shorter radiation courses, MRI surveillance and immunotherapy with SABR.

Presidential Symposium explores the messaging and methods of communicating radiotherapy's value

The Presidential Symposium explored how to communicate radiation therapy’s value, from organ preservation and AI to patient perceptions and stakeholder views.

Surveillance is not observation: MAVERICK challenges routine prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC)

The Phase III MAVERICK trial examines brain MRI surveillance without prophylactic cranial irradiation in small cell lung cancer cases

New Waves from the Bone Thugs: Modernizing Radiotherapy for Plasma Cell Neoplasms

Emerging research explores lower-dose, shorter-course radiation therapy for multiple myeloma and combined treatment for solitary plasmacytoma, with promising pain relief, response and progression-free survival outcomes.

Does brachytherapy boost improve outcomes for intermediate-risk prostate cancer?

The phase III GETUG P05 trial found a brachytherapy boost did not improve five-year PSA-PFS over dose-escalated EBRT alone in intermediate-risk prostate cancer.